Nearly 70 players engaged in the evaluation of therapeutic candidates based on a number of psychedelic compounds- Roots Analysis'

Your avatar
EL
Ella

Psychedelic substances have been demonstrated to interact with a variety of neurotransmitter pathways, including those involving serotonin, acetylcholine, norepinephrine, and dopamine. Currently, several stakeholders in the pharmaceutical industry are actively engaged in the efforts to develop leads based on natural and synthetic derivatives of psychedelic substances. Further, experts believe that psychedelics, at appropriate doses, can be used to address some of the serious psychological implications associated with the COVID-19 pandemic. 

 

 

To order this 250+ page report, which features 120+ figures and 135+ tables, please visit this - https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market.html

 

 

The over USD 6.5 billion (by 2030) financial opportunity within the psychedelic therapeutics market has been analyzed across the following segments:

Target Disease Indication

Anxiety and Depression

Trauma

Pain Disorder

Sleep related Disorder

 

Origin of Psychedelic Substance

Natural

Synthetic

 

Type of Psychedelic Substance

Gamma-hydroxybutyrate

Ketamine

MDMA

Psilocybin

 

Route of Administration

Oral

Intranasal

Sublingual

 

Key Geographies

North America

Europe

Asia-Pacific

 

The Global Psychedelic Therapeutics Market, 2020-2030” report features the following companies, which we identified to be key players in this domain:

Celon Pharma

iX Biopharma

MAPS Public Benefit

MindMed

Janssen Pharmaceuticals

Jazz Pharmaceutical

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction
 

4. Market Landscape: Psychedelic Therapeutics
 

5. Company Profiles
 

6. Clinical Trial Analysis 
 

7. Clinical Trial Site Analysis
 

9. Key Opinion Leader (KOL) Analysis

 

8. Academic Grants Analysis
 

10. Partnerships and Collaborations
 

11. Mergers and Acquisitions
 

12.  Market Forecast and Opportunity Analysis
 

13. Concluding Remarks
 

14. Executive Insights

 

15. Appendix 1: Tabulated Data

 

16. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com  

 

Keep discovering on Mamby:

If you liked this post, you may also be interested in...
O
Information Work with us Contact Terms and Conditions FAQs
© 2021, Mamby Investments